Register Login

NANO-X IMAGING LTD. (NNOX)

Director Meltzer Erez 🟢 acquired 480.8K shares (3 derivative) of Nano-X Imaging Ltd. (NNOX) at $23.84 ($9.0M) Transaction Date: Aug 10, 2026 | Filing ID: 087547

Full text
Register to leave comments
  • News bot Aug. 11, 2026, 1:25 p.m.

    🔍 Meltzer Erez (Director)

    Company: Nano-X Imaging Ltd. (NNOX)

    Report Date: 2026-08-10

    Transaction Summary:

    • Total transactions: 5
    • Derivative instruments: 3
    • Holdings reported: 4
    • Total shares acquired: 9,443
    • Total shares held: 550,818

    Detailed Transactions and Holdings:

    • Acquired 9,443 shares of Ordinary Shares at $1.03 per share (Direct)
      Date: 2026-08-10 | Code: P | equity_swap_involved: 0 | shares_owned_after: 45,443.00 | transaction_form_type: 4 | Footnotes: F1, F1
    • Holds 0 shares of Ordinary Shares (Direct)
      Date: 2026-08-10 | Code: H | shares_owned_after: 60,584.00 | Footnotes: F2
    • Holds 40,234 shares of Stock Option (right to buy ordinary shares) at $2.21 per share (Derivative)
      Date: 2026-08-10 | Code: H | Expires: 2030-02-11 | shares_owned_after: 40,234.00 | Footnotes: F2, F3
    • Holds 300,000 shares of Stock Option (right to buy ordinary shares) at $23.84 per share (Derivative)
      Date: 2026-08-10 | Code: H | Expires: 2032-01-02 | shares_owned_after: 300,000.00 | Footnotes: F2, F4
    • Holds 150,000 shares of Stock Option (right to buy ordinary shares) at $11.52 per share (Derivative)
      Date: 2026-08-10 | Code: H | Expires: 2034-04-16 | shares_owned_after: 150,000.00 | Footnotes: F2, F5

    Footnotes:

    • F1: The ordinary shares reported in this row were purchased by Oud Nof, a company wholly owned by the Reporting Person.
    • F2: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
    • F3: The options reported in this row were granted to the Reporting Person by the Issuer on February 11, 2020 and are fully vested and exercisable as of the date of this report.
    • F4: The options reported in this row were granted to the Reporting Person by the Issuer on January 2, 2020 and are fully vested and exercisable as of the date of this report.
    • F5: The options reported in this row were granted to the Reporting Person by the Issuer on April 16, 2024, and vest and become exercisable in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant, and an additional 6.25% of the options vest on a quarterly basis over the following three years such that all options reported in this row will be fully vested on the four-year anniversary of that grant date (April 16, 2028).
    • REMARKS: See Exhibit 24.1: Power of Attorney

Search

News categories